Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion?
Edwards Lifesciences (NYSE:EW) reported Q2 2026 net sales of $1.74B, up 13.6% YoY, and adjusted EPS of $0.78 vs $0.74 expected. TMTT revenue rose 47.3% YoY to $195.9M. The company raised full-year sales growth guidance to 10%–11% ($6.6B–$6.9B) and reaffirmed adjusted EPS of $2.95–$3.05.
How this was made
The 30-second read
Why it matters
Traders can use the raised full-year sales growth guidance (10%–11%) and the 47.3% TMTT growth rate to update near-term revenue expectations, while monitoring whether GAAP profitability and tax effects normalize in subsequent quarters.
Market read
A guidance raise tied to strong TMTT growth is the core catalyst, offset by GAAP EPS weakness and tax-related headwinds.
What to watch
Hospital cath lab capacity limits and elective procedure constraints could slow TMTT conversion into sustained margin expansion, even if adoption remains strong.
Background
The piece frames Edwards’ Q2 2026 performance around accelerating adoption of next-generation structural heart devices, especially TMTT (PASCAL, EVOQUE, SAPIEN M3).
Ticker impact
Edwards Lifesciences reported Q2 2026 net sales of $1.74B, raised full-year sales growth guidance to 10%–11%, and showed TMTT revenue up 47.3% to $195.9M.
Bias toward near-term upside as guidance is raised, but GAAP EPS weakness and tax-related charges may cap the reaction.
The text provides specific, time-stamped financial results (net sales, adjusted EPS) plus an explicit guidance raise and segment growth rate, which typically drive earnings revisions and positioning.
Market effects
Reinforces demand strength in structural heart transcatheter therapies, potentially supporting sentiment for the broader TAVR/TMVR device supply chain.
Mentions global market resilience for SAPIEN platform and FX friction, implying mixed regional translation effects.
Medicare reimbursement proposal could matter for US procedure volumes, with read-through to global structural heart procedure demand.
Counterpoint
GAAP EPS deterioration and large tax-related charges (effective tax rate 53.6%) suggest the quality of earnings may be weaker than the revenue growth headline implies.
Key entities
- companyEdwards Lifesciences
US-listed structural heart device maker reporting Q2 2026 results, segment growth, and raised full-year sales guidance.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Proposed reimbursement expansion for certain asymptomatic severe aortic stenosis patients, potentially expanding eligible TAVR population.
